We have 4 of 65 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Results underscore the therapeutic potential of VIIIe and its analogs as promising lead candidates for the development of selective, DNA-targeted anticancer agents.
Experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
This integrated study pinpointed ACEB-Cl as a promising VEGFR-2targeted anticancer lead compound with strong inhibitory potency, and a clearly defined mechanism of action, supporting its progression for further improvement.
Findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
